부광약품
ABOUT BUKWANG
Company Introduction
Vision & Mission
History
Manufacturing Facilities
Subsidiaries & Affiliates
Contact us
R&D
R&D Facilities
Pipeline
Latuda
JM-010
CP-012
Open Innovation
NEWS
IR
Financial Information
IR Reports
ANNUAL REPORT
PRODUCTS
Product Search
ETC
OTC
Health Functional Food
Personal Care Products
HOME
CONTACT US
KR
KR
EN
ABOUT BUKWANG
Company Introduction
Vision & Mission
History
Manufacturing Facilities
Subsidiaries & Affiliates
Contact us
R&D
R&D Facilities
Pipeline
Latuda
JM-010
CP-012
Open Innovation
JaguAhr
Protekt
NEWS
News
IR
Financial Information
IR Reports
ANNUAL REPORT
PRODUCTS
Product Search
ETC
OTC
Health Functional Food
Personal Care Products
NEWS
HOME
NEWS
NEWS
NEWS
ALL
Company news
Product news
R&D news
R&D news | Bukwang Pharmaceutical Co., Ltd. entered into a license tra..
On August 14, 2018, the two companies signed a contract to transfer all rights o..
2018.08.14
R&D news | Bukwang Pharmaceutical Co., Ltd. completed global phase 2b s..
- 400 patient enrollment in 61 sites (US & KR)Bukwang Pharmaceutical Co., Lt..
2018.08.07
R&D news | Bukwang Pharmaceutical Co., Ltd. expects to complete patient..
More than 360 patients dosed out of 400 patients in the US and KoreaMLR-1023, a ..
2018.07.04
R&D news | Bukwang-OCI, Pharmaceutical and Bio industry Business allian..
- Both companies agree 50:50 joint venture on May 30th- Starting in July, a join..
2018.05.30
R&D news | Bukwang Pharmaceuticals, began to expand the lineup of antic..
Bukwang has recently established a small but solid position in the anticancer dr..
2018.05.18
R&D news | Bukwang Pharm, income from AurKa Pharma investment - Upfront..
Bukwang Pharmaceutical announced that it owns a 5.4 percent stake in AurKa Pharm..
2018.05.15
1
2
3
4
5